Knollwood Investment Advisory’s Vertex Pharmaceuticals VRTX Stock Holding History

Knollwood Investment Advisory’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.23M	Hold	4,988	–	–	0.22%	89
2025 Q4	$2.26M	Hold	4,988	–	–	0.21%	102
2025 Q3	$1.95M	Hold	4,988	–	–	0.18%	125
2025 Q2	$2.22M	Hold	4,988	–	–	0.21%	110
2025 Q1	$2.42M	Hold	4,988	–	–	0.27%	98
2024 Q4	$2.01M	Hold	4,988	–	–	0.21%	118
2024 Q3	$2.32M	Hold	4,988	–	–	0.25%	102
2024 Q2	$2.34M	Buy	4,988 +828	+20%	+$359K	0.26%	91
2024 Q1	$1.74M	Hold	4,160	–	–	0.31%	58
2023 Q4	$1.69M	Buy	+4,160	New	+$1.54M	0.35%	54

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Knollwood Investment Advisory's VRTX Position: Q1 2026 in Review

Knollwood Investment Advisory held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2026 at 4,988 shares worth $2.23M. The position accounts for 0.22% of the portfolio, ranked #89.

Knollwood Investment Advisory first reported a position in VRTX in Q4 2023 and has held it in 10 quarters since. The position peaked at $2.42M in Q1 2025. 1,691 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Knollwood Investment Advisory held 4,988 shares of Vertex Pharmaceuticals worth $2.23M as of Q1 2026.
Knollwood Investment Advisory left its Vertex Pharmaceuticals share count unchanged in Q1 2026.
Vertex Pharmaceuticals made up 0.22% of Knollwood Investment Advisory's portfolio in Q1 2026, its #89 holding.
Knollwood Investment Advisory first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
Knollwood Investment Advisory's Vertex Pharmaceuticals position peaked at $2.42M in Q1 2025.
1,691 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Knollwood Investment Advisory's 13F filing for Q1 2026, filed 14 May 2026.